Search

Microsoft doesn’t make headlines much anymore. But MSFT stock has been rock solid. Lately, it’s been much better than that.

Stock market predictions are easy to make. They’re also utterly meaningless - and potentially dangerous if you listen to them.

We’re making some portfolio adjustments today.

Cabot explains how the Dow could reach 14,000 in 2011.

It’s time to sell EMAN. I think eMagin remains a mediocre company that has excellent technology and which will continue to have modest success in its military markets. But I don’t think this is “the next big thing.”

Today, Goldman Sachs Group (GS) reported a tremendous third quarter, with earnings per share (EPS) of $4.88 vs. Wall Street’s consensus estimate of $3.82, and up 47% vs. $2.90 EPS a year ago (December year-end).

This biopharmaceutical firm acquires, rebrands and reprices drugs for sale in the U.S., with many that treat inflammatory conditions, including a few that take aim at rare diseases.

The healthcare industry has had its share of ups and downs, with most of the attention being showered on the biotechs that hope to produce COVID-19 vaccines. But after the recent outlook upgrade of today’s recommendation, investors may want to broaden their healthcare watch list.

For now our positions remain in great shape, and this week we are adding a stock that we successfully traded in March, and has shown no signs of pulling back after an earnings blowout last week.

Today’s recommendation had been in a slow, steady uptrend for years, though it got dented with everything else in March of this year.

MarketWatch reports that Cabot Market Letter owes its strong performance in 2007 to market timing and stock selection.

It’s been a relatively quiet week in the market, with the major indexes mostly up in the 1% range after this morning’s open, though the action has been news-driven as every economic report and Fed speech is picked over for clues to the path of interest rates.

Overall, it’s been an interesting week: The major indexes have bounced nicely even including a morning selloff on the jobs report, up in the 3% range, and early this week we did see some unusual upside breadth—Tuesday’s NYSE up volume outpaced down volume by 20- to 25-to-1 (depending on exactly how you measure it), which, when coming after a selling deluge, has frequently marked low points.

Cabot offers two very different options trading services to better serve a variety of investors. Here are the differences you need to know.

It’s been another sour week for the major indexes, with all of them coming into Friday down in the 2.5% to 4.5% range. More important to us is that many of the intermediate-term and secondary positives of the past few weeks have vanished—the intermediate-term uptrend has cracked at this point, the number of stocks hitting new lows is elevated and our Aggression Index (growth vs. defensive stocks) is also off its green light.

The indexes are flat-ish this week after this morning’s upmove, which marks a normal consolidation after the strong inflation report-induced rally last week.

Investors hate being told to do nothing. And when the market is chopping up and down like a roller coaster, it’s especially hard. Maybe you want to pick up some screaming bargains, or maybe you’re itching to sell everything at any price. But those times, when the market has no...

The big news in the marijuana industry this week is that the Tilray/Aphria merger is complete, turning these two Canadian firms into the biggest marijuana company in the world—for now.